1. Bray F, Ferlay J, Soerjomataram I, et al. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394-424.
2. European Association for the Study of the Liver. (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236.
3. Vogel A, Cervantes A, Chau I, et al. (2018) Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol
29:iv238–55.
4. Llovet JM, Ricci S, Mazzaferro V, et al. (2008) SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390.
5. Cheng AL, Kang YK, Chen Z, et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34.
6. Bruix J, Qin S, Merle P, et al. (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56-66.
7. El-Khoueiry AB, Sangro B, Yau T, et al. (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389:2492-2502.
8. Sharma P, Allison JP. (2015) The future of immune checkpoint therapy. Science 348:56–61.
9. Scheiner B, Kirstein MM, Hucke F, et al. (2019) Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. Aliment Pharmacol Ther 49:1323–33.
10. Zhu AX, Finn RS, Edeline J, et al. (2018) Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 19(7):940–952
11. Lencioni R, Llovet JM. (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52-60.
12. Rizvi NA, Mazières J, Planchard D, et al. (2015) Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 16(3):257-265.
13. Weber JS, D'Angelo SP, Minor D, et al. (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16(4):375-84.
14. McDermott DF, Drake CG, Sznol M, et al. (2015) Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol. 20;33(18):2013-20.
15. Yau T, Park JW, Finn RS, et al. (2019) CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line(1L) treatment in patients (PTS) with advanced hepatocellular carcinoma (aHCC). Ann Oncol 30:v874–5.
16. Yau T, Hsu C, Kim TY, et al. (2019) Nivolumab in advanced hepatocellular carcinoma: sorafenib experienced Asian cohort analysis. J Hepatol 71:543-552.
17. Lee CH, Lee YB, Kim MA, et al. (2020) Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment. Clin Mol Hepatol. 26(3):328-339.
18. Choi WM, Choi J, Lee D, et al. (2020) Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma. Hepatol Commun. 16;4(7):1073-1086.
19. Wilhelm SM, Dumas J, Adnane L, et al. (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129(1):245–255
20. Chen S, Cao Q, Wen W, Wang H. (2019) Targeted therapy for hepatocellular carcinoma: challenges and opportunities. Cancer Lett 460:1-9.
21. Finn RS, Merle P, Granito A, Huang YH, et al. (2018) Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol. 69(2):353-358.
22. Cabibbo G, Celsa C, Enea M, et al. (2020) Optimizing sequential systemic therapies for advanced hepatocellular carcinoma: A decision analysis. Cancers (Basel). 31;12(8):2132.
23. Ogasawara S, Ooka Y, Itokawa N, et al. (2020) Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan. Invest New Drugs. 38(1):172-180.